Heme iron polypeptide for the management of anaemia of chronic kidney disease

Journal of Clinical Pharmacy and Therapeutics

Volumn 40, Issue 4, 2015, Pages 386-390

  Dull, R B ^a   Davis, E ^a  

^a CREIGHTON UNIVERSITY   (United States)

Author keywords

anaemia; chronic kidney disease; heme iron; heme iron polypeptide; oral iron

Indexed keywords

FERROUS SULFATE; HEME IRON POLYPEPTIDE; HEMOGLOBIN; POLYPEPTIDE; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; UNCLASSIFIED DRUG; IRON DERIVATIVE; PEPTIDE;

ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; HEMATOCRIT; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON SUPPLEMENTATION; LOW DRUG DOSE; OPEN STUDY; PATIENT COMPLIANCE; PERITONEAL DIALYSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TRANSFERRIN BLOOD LEVEL; TREATMENT DURATION; ANEMIA, IRON-DEFICIENCY; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; COMPLICATION; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANEMIA, IRON-DEFICIENCY; HUMANS; IRON COMPOUNDS; PEPTIDES; RENAL INSUFFICIENCY, CHRONIC;

EID: 84936985403     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12281     Document Type: Article

References (18)

1. Dowling T,. Prevalence, etiology, and consequences of anemia and clinical and economic benefits of anemia correction in patients with chronic kidney disease: an overview. Am J Health-Sys Pharm, 2007; 64: S3-S7.
2. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl, 2012; 2: 279-335.
3. Hudson JQ, Comstock TJ,. Considerations for optimal iron use for anemia due to chronic kidney disease. Clin Ther, 2011; 23: 1637-1671.
4. Macdougall IC, Tucker B, Thompson J, et al,. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int, 1996; 50: 1694-1699.
5. Young B, Zaritsky J,. Hepcidin for clinicians. Clin J Am Soc Nephrol, 2009; 4: 1384-1387.
6. Fishbane S, Shapiro W, Dutka P, et al,. A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int, 2001; 60: 2406-2411.
7. Fundin R, Jaichenko J, Shostak A, et al,. Correction of uremic iron deficiency anemia in hemodialyzed patients: a prospective study. Nephron, 1998; 79: 299-305.
8. Hallberg L, Bjorn-Rasmussen E, Howard L, et al,. Dietary heme iron absorption. A discussion of possible mechanisms for the absorption-promoting effect of meat and for the regulation of iron absorption. Scand J Gastroenterol, 1979; 14: 769-779.
9. Seligman PA, Moore GM, Schleicher RB,. Clinical studies of HIP: an oral heme-iron product. Nutr Res, 2000; 20: 1279-1286.
10. Nam TS, Shim JY, Kim B, et al,. Clinical study on the iron absorption from heme-iron polypeptide and nonheme iron. Nutritional Sciences, 2006; 9: 295-300.
11. Macdougall IC,. Strategies for iron supplementation: oral versus intravenous. Kidney Int, 1999; 55 (Suppl 69): S61-S66.
12. Frykman E, Bystrom M, Jansson U, et al,. Side effects of iron supplements in blood donors: superior tolerance of heme iron. J Lab Clin Med, 1994; 123: 561-564.
13. Nagaraju SP, Cohn A, Akbari A, et al,. Heme iron polypeptide for the treatment of iron deficiency anemia in non-dialysis chronic kidney disease patients: a randomized controlled trial. BMC Nephrology, 2013; 14: 64.
14. Nissenson AR, Berns JS, Sakiewicz P, et al,. Clinical evaluation of heme iron polypeptide: sustaining a response in rHuEPO in hemodialysis patients. Am J Kidney Dis, 2003; 42: 325-330.
15. Barrclough KA, Brown F, Hawley C, et al,. A randomized controlled trial of oral heme iron polypeptide versus oral iron supplementation for the treatment of anaemia in peritoneal dialysis: HEMATOCRIT trial. Nephrol Dial Transplant, 2012; 27: 4146-4153.
16. Geisser P, Burckhardt S,. The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics, 2011; 3: 12-33.
17. Barraclough KA, Noble E, Leary D, et al,. Rationale and design of the oral heme iron polypeptide against treatment with oral controlled release iron tablets trial for the correction of anaemia in peritoneal dialysis patients (HEMATOCRIT trial). BMC Nephrology, 2009; 10: 1-7.
18. Proferrin® ES [package insert]. Frederick, CO: Colorado Biolabs, 2013.